Dec. 8 (UPI) --The U.S. Food and Drug Administration on Monday announced the approval of the first hematopoietic stem cell transplant therapy to treat patients with rare but severe aplastic anemia.
The FDA has approved omidubicel-onlv (Omisirge, Gamida Cell Ltd.) as the first hematopoietic stem cell transplant therapy for patients with severe aplastic anemia (SAA). Specifically, omidubicel is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results